FOR IMMEDIATE RELEASE

SK Biopharmaceuticals' 2022 Sustainability Report Reinforces its Commitment to ESG Management

SK Biopharmaceuticals' report details a plan for the future milestones in five sustainability pillars

SK Biopharmaceuticals unveils a mid/long-term strategy to achieve "Net Zero" by 2040

Pangyo, Gyeonggi Province, Korea, July 13, 2022 – SK Biopharmaceuticals, Co, ltd. today released the "2022 SK Biopharmaceuticals Sustainability Report" to highlight key achievements and define its goals in environmental, social and governance (ESG). The report includes the company's vision toward "A New Decade" to strengthen its capabilities and expand its business.

SK Biopharmaceuticals has taken significant steps to promote sustainability practices, led by its Board of Directors. The 2022 report highlights progress that has been made as well as key action plans to be implemented in the five main sustainability areas: creation of healthcare values; minimized environmental impact; sustainable partnership; competent and happy employees; transparent and ethical operation.

"SK Biopharmaceuticals has led the creation of social and economic value, even facing the COVID-19 pandemic, increasing its presence in the top four global markets including the U.S., Europe, Japan and China," said Jeong-Woo Cho, President & CEO of the company. "We remain committed to improving social and environmental conditions both in the global biopharmaceuticals industry and in our communities while strengthening ESG management to ensure that we can continue to provide safe high-quality medicines in the global market."

With the expansion of its anti-seizure medication, cenobamate, into key markets including the U.S., SK Biopharmaceuticals created social value amounting to approximately KRW152.1 billion in the "creation of healthcare values" area. By 2023, the company aims to maximize its social value with its capabilities and business competitiveness and lead global central nervous system field by providing its innovative treatments as well as expanding its medicines in markets more than two-fold compared to in 2020.

In the "minimized environmental impact" area, SK Biopharmaceuticals sourced 54% of its power in 2021 from renewable energy through K-RE100, and developed a mid and long-term plan for the ambitious "Net Zero by 2040" initiative unveiled last year. To achieve a 33% carbon emissions reduction by 2030 and a further 66% reduction by 2035, it will build an emission inventory system by 2025, which will allow the company to implement its greenhouse gas reduction plan across the supply chain and to directly engage in emission reduction activities beginning in 2026.

In the "sustainable partnership" area, the company's goal is to encourage all its partners to adhere to its ESG Guidelines developed last year and to participate in its ESG risk assessment. In the "competent and happy

employees" area, SK Biopharmaceuticals will implement a unique career development system. In the "transparent and ethical operation" area, the company will focus on minimizing the risk in anti-corruption and compliance practices and increasing stakeholders' trust.

As one of the leading global pharmaceutical companies, SK Biopharmaceuticals has been strengthening its governance system to the highest level by adopting ESG practices for its U.S. subsidiary, SK life science. In February 2022, SK Biopharmaceuticals became the first Korean biopharmaceutical company to join the Pharmaceutical Supply Chain Initiative (PSCI), a global initiative which aims to promote responsible practices across the global healthcare supply chain. The company continues to increase its commitment to ESG management, which includes preemptively responding to ESG risks in its global partnerships and working with a broader range of ESG rating organizations.

About Cenobamate

Cenobamate is an anti-seizure medication (ASM) discovered and developed by SK Biopharmaceuticals and SK life science. While the precise mechanism by which cenobamate exerts its therapeutic effect is unknown, it is believed to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. It is also a positive allosteric modulator of the γ-aminobutyric acid ($GABA_A$) ion channel.

Cenobamate is approved in the United States for the treatment of partial-onset seizures in adults and is available under the brand name XCOPRI® (cenobamate tablets) CV. Cenobamate can be combined with other ASMs or used alone. The recommended initial dosage of cenobamate is 12.5 mg once-daily, with titration every two weeks; it is available in six tablet strengths for once-daily dosing: 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg.

Cenobamate is also approved in the European Union and the United Kingdom for the adjunctive treatment of focal-onset (partial-onset) seizures with or without secondary generalization in adult patients with seizures that have not been adequately controlled despite a history of treatment with at least two anti-epileptic medicinal products and is marketed by Angelini Pharma under the brand name ONTOZRY®.

Additionally, cenobamate is in clinical development in Asia. Ono Pharmaceutical and Ignis Therapeutics have the rights to develop and commercialize cenobamate in Japan and in the Greater China region, respectively. SK Biopharmaceuticals has recently entered into an exclusive licensing agreement with Endo for cenobamate in Canada.

IMPORTANT SAFETY INFORMATION AND INDICATION FOR XCOPRI® (cenobamate tablets) CV

DO NOT TAKE XCOPRI IF YOU:

- Are allergic to cenobamate or any of the other ingredients in XCOPRI.
- Have a genetic problem (called Familial Short QT syndrome) that affects the electrical system of the heart.

XCOPRI CAN CAUSE SERIOUS SIDE EFFECTS, INCLUDING:

Allergic reactions: XCOPRI can cause serious skin rash or other serious allergic reactions which may affect organs and other parts of your body like the liver or blood cells. You may or may not have a rash with these types of reactions. Call your healthcare provider right away and go to the nearest emergency room if you have any of the following: swelling of your face, eyes, lips, or tongue, trouble swallowing or breathing, a skin rash, hives, fever, swollen glands, or sore throat that does not go away or comes and goes, painful sores in the mouth or around your eyes, yellowing of your skin or eyes, unusual bruising or bleeding, severe fatigue or weakness, severe muscle pain, frequent infections, or infections that do not go away. **Take XCOPRI exactly as your healthcare provider tells you to take it. It is very important to increase your dose of XCOPRI slowly, as instructed by your healthcare provider.**

QT shortening: XCOPRI may cause problems with the electrical system of the heart (QT shortening). Call your healthcare provider if you have symptoms of QT shortening including fast heartbeat (heart palpitations) that last a long time or fainting.

Suicidal behavior and ideation: Antiepileptic drugs, including XCOPRI, may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call your health care provider right away if you have any of the following symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying; attempting to commit suicide; new or worse depression, anxiety, or irritability; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); or other unusual changes in behavior or mood.

Nervous system problems: XCOPRI may cause problems that affect your nervous system. Symptoms of nervous system problems include: dizziness, trouble walking or with coordination, feeling sleepy and tired, trouble concentrating, remembering, and thinking clearly, and vision problems. **Do not drive, operate heavy machinery, or do other dangerous activities until you know how XCOPRI affects you**.

Do not drink alcohol or take other medicines that can make you sleepy or dizzy while taking XCOPRI without first talking to your healthcare provider.

DISCONTINUATION:

Do not stop taking XCOPRI without first talking to your healthcare provider. Stopping XCOPRI suddenly can cause serious problems. Stopping seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus).

DRUG INTERACTIONS:

XCOPRI may affect the way other medicines work, and other medicines may affect how XCOPRI works. **Do not start or stop other medicines without talking to your healthcare provider.** Tell healthcare providers about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

PREGNANCY AND LACTATION:

XCOPRI may cause your birth control medicine to be less effective. **Talk to your health care provider about the best birth control method to use.**

Talk to your health care provider if you are pregnant or plan to become pregnant. It is not known if XCOPRI will harm your unborn baby. Tell your healthcare provider right away if you become pregnant while taking XCOPRI. You and your healthcare provider will decide if you should take XCOPRI while you are pregnant. If you become pregnant while taking XCOPRI, talk to your healthcare provider about registering with the North American Antiepileptic Drug (NAAED) Pregnancy Registry. The purpose of this registry is to collect information about the safety of antiepileptic medicine during pregnancy. You can enroll in this registry by calling 1-888-233-2334 or go to www.aedpregnancyregistry.org.

Talk to your health care provider if you are breastfeeding or plan to breastfeed. It is not known if XCOPRI passes into breastmilk. Talk to your healthcare provider about the best way to feed your baby while taking XCOPRI.

COMMON SIDE EFFECTS:

The most common side effects in patients taking XCOPRI include dizziness, sleepiness, headache, double vision, and feeling tired.

These are not all the possible side effects of XCOPRI. Tell your healthcare provider if you have any side effect that

bothers you or that does not go away. For more information, ask your healthcare provider or pharmacist. **Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088** or at www.fda.gov/medwatch**.**

DRUG ABUSE:

XCOPRI is a federally controlled substance (CV) because it can be abused or lead to dependence. Keep XCOPRI in a safe place to prevent misuse and abuse. Selling or giving away XCOPRI may harm others and is against the law.

INDICATION:

XCOPRI is a prescription medicine used to treat partial-onset seizures in adults 18 years of age and older. It is not known if XCOPRI is safe and effective in children under 18 years of age.

Please see additional patient information in the Medication Guide. This information does not take the place of talking with your healthcare provider about your condition or your treatment.

Please see full Prescribing Information.

Media Inquiries
SK Biopharmaceuticals
Hyongki Park, Director of Communications
h.p.comm@sk.com

Jaehee Kang, Communications Manager
jaeheekang@sk.com